Emanuele Monda il 09/09/2026

Fabry Disease: Cardiac and Neurologic Involvement

Heart Fail Clin. 2026 Oct;22(4):451-462. doi: 10.1016/j.hfc.2026.07.005. Epub 2026 Jul 30.ABSTRACTCardiac and neurologic manifestations are common in Fabry disease (FD) and significantly impact prognosis and quality of life. Cardiac involvement includes hypertrophic cardiomyopathy, arrhythmias, and

Yajuan Li il 09/09/2026

Impact of hypertrophic pattern and obstruction on cardiovascular magnetic resonance myocardial strain and left atrioventricular coupling in hypertrophic cardiomyopathy: a retrospective study

Open Heart. 2026 Sep 9;13(2):e004215. doi: 10.1136/openhrt-2026-004215.ABSTRACTBACKGROUND: Hypertrophic cardiomyopathy (HCM) exhibits complex phenotypic heterogeneity. Left ventricular myocardial strain and atrioventricular coupling hold significant clinical value in cardiovascular diseases; however

Y Lu il 09/09/2026

Effect of cardiac myosin inhibitors on cardiac structure and myocardial fibrosis in obstructive hypertrophic cardiomyopathy: a meta-analysis of cardiac magnetic resonance outcomes

Clin Radiol. 2026 Jun 18;102:107416. doi: 10.1016/j.crad.2026.107416. Online ahead of print.ABSTRACTAIM: Recent advancements have introduced cardiac myosin inhibitors (CMIs) that have demonstrated significant efficacy in obstructive hypertrophic cardiomyopathy (oHCM). This meta-analysis aims to synt

Martha Caterina Faraguna il 06/09/2026

Epilepsy Is Part of the CNS Phenotype in Classic Infantile Pompe Disease

Neurol Genet. 2026 Sep 1;12(5):e200432. doi: 10.1212/NXG.0000000000200432. eCollection 2026 Oct.ABSTRACTBACKGROUND AND OBJECTIVES: Enzyme replacement therapy has not only significantly improved motor outcome and survival in patients with classic infantile Pompe disease, but also revealed previously